DISC 0974
Alternative Names: Anti-hemojuvelin monoclonal antibody - Disc Medicine/AbbVie; DISC-0974Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator AbbVie
- Developer AbbVie; Disc Medicine
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action HFE2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Anaemia; Myeloproliferative disorders
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 09 Dec 2024 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral)
- 09 Dec 2024 Pharmacodynamics data from preclinical studies in Anaemia and Inflammatory bowel disease released by Disc Medicine
- 08 Dec 2024 Efficacy and adverse events data from the phase Ib/IIa trial in Myeloproliferative disorders and Anemia released by Disc Medicine